Abstract
This study aims to evaluate the impact of resistance to fluoroquinolones on the short-term outcome of community-acquired urinary tract infections (UTIs) caused by Escherichia coli. Patients were identified and followed, during 2006, using the health care databases of the Emilia-Romagna Region. The outcome of interest was the treatment failure/short-term relapse (the re-isolation of E. coli from urine between 4 and 30 days after the first isolation). Resistance to fluoroquinolones increases the risk of treatment failure/short-term relapse in women with uncomplicated community-acquired UTIs caused by E. coli (Rate Ratio=1.85, 95% CI 1.32-2.60). The efficacy of fluoroquinolones for community-acquired UTIs of men was significantly modified by the resistance status of E. coli. Prescription of these agents was associated with a reduced occurrence of the outcome only in men with a ciprofloxacin sensitive first isolate (Rate Ratio=0.50, 95% CI 0.25-0.99). Resistance to fluoroquinolones of E. coli is a growing problem with a negative impact on the outcome of community-acquired UTIs; therefore, the prescription of these agents should be limited to infections for which they are recommended, avoiding their use in uncomplicated UTIs.
References
Mar 27, 2002·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·Patricia D BrownBetsy Foxman
Jun 19, 2004·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·Thomas M HootonLindsay E Nicolle
Jul 13, 2006·BJU International·Peter E Pertel, Daniel Haverstock
Sep 26, 2006·The Journal of Antimicrobial Chemotherapy·C A M McNultyM Thomas
Feb 13, 2007·International Journal of Antimicrobial Agents·Loren G MillerAngela W Tang
Feb 17, 2007·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·Ying Taur, Miriam A Smith
Mar 30, 2007·Clinical Microbiology and Infection : the Official Publication of the European Society of Clinical Microbiology and Infectious Diseases·C GagliottiUNKNOWN Emilia-Romagna Antibiotic Resistance Study Group
Citations
Feb 5, 2010·The Lancet Infectious Diseases·Matthew E FalagasDrosos E Karageorgopoulos
Apr 24, 2013·Avian Pathology : Journal of the W.V.P.A·Jin Hyun KimKi Seuk Kim
Jul 1, 2010·The Journal of Antimicrobial Chemotherapy·Matthew E FalagasStavros Athanasiou
Mar 12, 2011·The Journal of Antimicrobial Chemotherapy·Kees VeldmanFrank M Aarestrup
Aug 19, 2009·Antimicrobial Agents and Chemotherapy·Sofia MarakiMatthew E Falagas
Aug 23, 2011·Applied and Environmental Microbiology·Maria KarczmarczykSéamus Fanning
Mar 1, 2012·Canadian Journal of Microbiology·A WalktyM Alfa
Oct 14, 2006·BMC Geriatrics·Susan E HazelettKyle Allen
May 15, 2009·BMC Infectious Diseases·Sigrid Metz-GercekHelmut Mittermayer
Feb 24, 2016·The Journal of Antimicrobial Chemotherapy·F MoustafaJ Schmidt
Aug 14, 2012·Vaccine·Maria Luisa MoroUNKNOWN SaFoH1N1 working group
Sep 7, 2012·International Journal of Infectious Diseases : IJID : Official Publication of the International Society for Infectious Diseases·Teerapong MonmaturapojPramote Tragulpiankit
Nov 7, 2016·BMC Infectious Diseases·Catherine ZatorskiLarissa May
Feb 9, 2019·Tropical Animal Health and Production·Bui Phan Thu HangAnna Duse
Jul 23, 2009·Pharmacoepidemiology and Drug Safety·Carlo GagliottiMaria Luisa Moro
Oct 28, 2020·Antimicrobial Agents and Chemotherapy·Lotte JakobsenNiels Frimodt-Møller
Dec 12, 2020·Antimicrobial Resistance and Infection Control·M C MacKinnonS A McEwen
Jul 13, 2021·AIMS Microbiology·Ehwarieme Daniel AyobolaEjukonemu Francis Ejovwokoghene